Kelly Fitzgerald

68 posts

Kelly Fitzgerald banner
Kelly Fitzgerald

Kelly Fitzgerald

@KellyNFitz

GU oncology at UCSF | MSKCC fellowship alum | cancer immunology and metabolism | tweets are mine

San Francisco, CA शामिल हुए Nisan 2009
130 फ़ॉलोइंग269 फ़ॉलोवर्स
Kelly Fitzgerald
Kelly Fitzgerald@KellyNFitz·
Great talk by @MdArpita #ucsf at #IKCSNA25 succinctly summarizing options in the challenging setting of IO resistance in RCC. We are looking ahead to earlier implementation of HIF2a blockade and earlier access to trials for our patients. @KidneyCancer
Kelly Fitzgerald tweet media
English
1
2
19
3.8K
Kelly Fitzgerald रीट्वीट किया
Cancer Discovery
Cancer Discovery@CD_AACR·
From the May issue: 'Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in RCC brnw.ch/21wSSDz By Miya Hugaboom, @lena__wirth, Kelly Street, @nruthen16, Michael Atkins, Catherine Wu, @BraunMDPhD
Cancer Discovery tweet media
English
0
9
29
5.1K
Kelly Fitzgerald रीट्वीट किया
Juan C Osorio MD
Juan C Osorio MD@juanosoriomd·
Interested in myeloid cell anti-tumor immunity? I’ll be presenting at @theNCI Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity cassyni.com/events/Eg84FXZ…
English
2
7
23
2.4K
Kelly Fitzgerald रीट्वीट किया
Andy Hahn
Andy Hahn@OncHahn·
(1/3) Check out our multicenter, IIT of sitravatinib + nivolumab after ICI in patients with metastatic ccRCC shorturl.at/qGWgy This trial was terminated early (14 of 88 planned) but built upon our group’s experience with sitravatinib led by @PavlosMsaouel
Andy Hahn tweet mediaAndy Hahn tweet media
English
1
18
35
2.8K
Kelly Fitzgerald रीट्वीट किया
Kidney Cancer
Kidney Cancer@KidneyCancer·
Federal #kidneycancer research funding drops from $50 million to ZERO after 57% cut to CDMRP. All but 12 of the 35 disease research programs saw funding eliminated for 2025, including the Kidney Cancer Research Program. More about the impact on our blog. bit.ly/4hoXnCq
Kidney Cancer tweet mediaKidney Cancer tweet media
English
1
19
16
6.3K
Kelly Fitzgerald रीट्वीट किया
Kidney Cancer
Kidney Cancer@KidneyCancer·
UPDATE 3/12: Last night the House voted to cut 57% of federally funded medical and cancer research through the CDMRP. Vote moves on to Senate and, if passed, to be signed into law by the President. More details: kidneycancer.org/protect-federa…
Kidney Cancer@KidneyCancer

🚨Protect Federal Funding for Kidney Cancer Research🚨 Right now, @CDMRP is facing a devastating 57% cut that directly impacts federal #kidneycancer research funding. Tell your reps to vote in support of continued funding. Take action NOW - bit.ly/4hoXnCq

English
0
12
10
2.3K
Ziad Bakouny, MD, MSc
Ziad Bakouny, MD, MSc@ZiadBakouny·
Absolutely thrilled to receive funding through the Department of Defense's Concept Award mechanism to study mitochondrial mutations in RCC! Very thankful to @EdReznik, Craig Thompson, and @motzermd & all collaborators and mentors for the support! @MSKCancerCenter @MSK_DeptOfMed
Ziad Bakouny, MD, MSc tweet media
English
26
15
180
16.5K
Kelly Fitzgerald
Kelly Fitzgerald@KellyNFitz·
Interesting to consider a ‘very favorable risk’ subgroup of ccRCC patients and the role of VEGFR targeted therapies here. How will HIF2a blockade perform in these patients?
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)@TiansterZhang

#MartinZarba @DrDanielHeng @UCalgaryMed with IMDC very/favorable risk #kidneycancer — all regimens w excellent survival. Ipi-nivo doublet falls short in very favorable risk RCC. @ASCO #ASCO24 @OncoAlert

English
0
0
4
345
Kelly Fitzgerald रीट्वीट किया
Jonathan Rosenberg MD
Jonathan Rosenberg MD@DrRosenbergMSK·
Big news for bladder cancer in US! “On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer (la/mUC).”
English
2
26
116
8.9K
Kelly Fitzgerald रीट्वीट किया
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)@TiansterZhang·
Great news for our patients w #kidneycancer!! Belzutifan now approved in refractory disease based on #LITESPARK005 data from @AlbigesL et al. @kcCURE @KidneyCancer @kidneycan
Toni Choueiri, MD@DrChoueiri

JUST IN: @US_FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors! A great day for the field and a new option for our Kidney Cancer patients!!!! Via @ASCO #FDAAlerts @OncoAlert Study presented at @myESMO #ESMO3 by @AlbigesL

English
0
11
38
5.2K
Kelly Fitzgerald
Kelly Fitzgerald@KellyNFitz·
Happy to share our findings at #IKCSNA23! In our single-institution retrospective cohort, no evidence of superiority of either IO/IO or TKI/IO in #kidneycancer 1L tx with regard to PFS2, including in groups w/ sarcomatoid features, BAP1 mutation, or deep RECIST response.
Kelly Fitzgerald tweet media
English
0
8
21
2.3K
Kelly Fitzgerald रीट्वीट किया
Bradley McGregor
Bradley McGregor@BradMcG04·
Zanzalitinib with activity in refractory RCC with manageable safety profile even in those patients who had previously received cabozantinib @montypal @DrChoueiri @KidneyCancer
Bradley McGregor tweet mediaBradley McGregor tweet media
English
0
16
45
5.8K

खोजें

@MdArpita @KidneyCancer @lena__wirth @nruthen16 @BraunMDPhD @theNCI @PavlosMsaouel @ZiadBakouny